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Brief Definit ive Report
Pancreatic cancer has a poor prognosis because 
of late presentation, early metastases, and resis-
tance of tumor cells to conventional treatments 
such as radiation and chemotherapy. Although 
surgery can significantly extend survival in the 
small subset of eligible patients, most patients 
ultimately relapse and succumb. Indeed, patients 
with metastatic disease have a median survival 
of between 2 and 6 mo. Despite extensive investi-
gation, the cytotoxic agent gemcitabine remains 
the standard of care offering only a modest sur-
vival benefit (Burris et al., 1997). In view of 
these disappointing results, novel therapeutic 
approaches are desperately needed.
The main subtype of pancreatic cancer is 
pancreatic ductal adenocarcinoma (PDA; Hezel 
et al., 2006). Somatic mutations in human PDA 
involves four canonical genes, including acti-
vating mutations in KRAS in >95% of cases 
(Smit et al., 1988). Additional insights to PDA 
pathogenesis have come from investigating the 
dysregulation of pathways operant during pan-
creatic development. These include the Notch, 
Wnt, and Hedgehog signaling pathways, which 
are mutated or up-regulated in most human 
pancreatic cancers (Jones et al., 2008).
The Notch signaling pathway controls cell 
fate decisions important for tissue integrity dur-
ing metazoan development and is aberrantly ac-
tivated in many carcinomas including pancreatic 
cancer (Miyamoto et al., 2003). Notch receptors 
are transmembrane proteins that direct tissue de-
velopment by influencing cellular differentiation, 
proliferation, and death. There are four Notch 
receptors identified in humans and mice, Notch 
1–4, and they contain cytoplasmic domains that 
serve as tethered transcription factors. Notch 
receptors use a unique signaling mechanism that 
is initiated by interaction with neighboring cells 
that bear cell surface ligands such as Delta or 
Jagged. Once the Notch receptor is engaged, 
this triggers extracellular proteolysis by TACE 
and finally culminates in the gamma secretase–
dependent intracellular proteolysis and release 
of the Notch intracellular domain (NICD). NICD 
translocates to the nucleus where it activates 
the transcription of Notch target genes.
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Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease that is refractory to 
medical intervention. Notch pathway antagonism has been shown to prevent pancreatic 
preneoplasia progression in mouse models, but potential benefits in the setting of an estab-
lished PDA tumor have not been established. We demonstrate that the gamma secretase 
inhibitor MRK003 effectively inhibits intratumoral Notch signaling in the KPC mouse model 
of advanced PDA. Although MRK003 monotherapy fails to extend the lifespan of KPC mice, 
the combination of MRK003 with the chemotherapeutic gemcitabine prolongs survival. 
Combination treatment kills tumor endothelial cells and synergistically promotes widespread 
hypoxic necrosis. These results indicate that the paucivascular nature of PDA can be ex-
ploited as a therapeutic vulnerability, and the dual targeting of the tumor endothelium and 
neoplastic cells by gamma secretase inhibition constitutes a rationale for clinical translation.
© 2012 Cook et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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(Hingorani et al., 2005). The KPC model has previously 
accurately predicted the failure of gemcitabine (Olive et al., 
2009) and the activity of CD40 ligand immunotherapy 
(Beatty et al., 2011) in patients; therefore, KPC mice with 
established tumors were used to evaluate the cell-intrinsic and 
microenvironment effects of GSI treatment. We find that GSI 
is partially active as a monotherapy in affecting both neo-
plastic and endothelial cells, but the magnitude of these effects 
only becomes preclinically evident by the co-administration 
of gemcitabine. An evaluation of the PDA tissue demonstrates 
that the sparse intratumoral endothelial cells serve as a major 
target of GSI and gemcitabine combination treatment, revealing 
a novel combination to consider for clinical translation.
RESULTS AND DISCUSSION
The Notch pathway is activated in human  
and mouse PDA and can be inhibited by a GSI
Consistent with prior studies (Hingorani et al., 2003; Miyamoto 
et al., 2003), we used immunohistochemistry and in situ hybrid-
ization to confirm that many components of the Notch pathway 
were present in neoplastic and microenvironment cells in mouse 
and human PanIN and PDA specimens (Fig. 1, A–C). Indeed, 
DLL4 and Jagged1 were detected in both the vasculature and 
stromal cells surrounding neoplastic cells (Fig. 1 A), and Notch 3 
was detected in both tumor and stromal cells (Fig. 1 A). Addi-
tionally, Hes1 and Hey2 were both detected in neoplastic 
cells (Fig. 1 B), and Hey2 also in intratumoral endothelial 
cells (Fig. 1 B). Many Notch pathway genes are direct tran-
scriptional targets of NICD and thus can be used to determine 
pathway inhibition (Bray and Bernard, 2010). Accordingly, 
In normal adult pancreas, Notch and its ligands are ex-
pressed in low or undetectable levels (Miyamoto et al., 2003). 
In preinvasive pancreatic intraepithelial neoplasia (PanIN) and 
fully invasive PDA there are prominent elevations in expression 
of these factors and an associated induction of transcriptional 
target genes, such as HES-1 (Hairy and Enhancer of Split 1), 
consistent with activation of this pathway during malignant 
progression (Miyamoto et al., 2003). Mouse models have im-
plicated Notch activation in pancreatic centroacinar cells, a 
proposed precursor cell of PDA (Hingorani et al., 2003; Stanger 
et al., 2005). Additionally, a transgenic mouse model of acinar 
metaplasia implicated the critical importance of Notch signaling 
in neoplasia, as the gamma secretase inhibitor (GSI) DAPT 
reversed the in vitro phenotype of acinar cell trans-differentiation 
and transformation (Miyamoto et al., 2003). Finally, a recent 
investigation used the GSI MRK003 to demonstrate selective 
cytotoxicity against human pancreatic cancer cells in culture 
and the prevention of pancreatic cancer formation in a mouse 
model (Plentz et al., 2009).
Given the importance of oncogenic K-ras in pancreatic 
cancer tumorigenesis and the requirement for Notch signaling 
in Ras transformation, Notch pathway inhibition is a logical 
therapeutic target for pancreatic cancer patients (Fitzgerald 
et al., 2000). As prior studies focused on the prevention of 
pre-neoplastic progression, we sought to determine the activity 
of GSI in mice with radiologically evident invasive PDA. 
Accordingly, we used the KPC mouse model of PDA, a model 
which recapitulates the cardinal pathophysiological aspects 
of human PDA and is based upon the pancreatic specific 
endogenous expression of KrasG12D and Trp53R172H alleles 
Figure 1. Notch pathway components are 
expressed in human and mouse PDA and 
can be decreased by MRK003. (A) Expression 
of Notch ligands (DLL4 and Jagged1) and  
receptor (Notch 3) in mouse (left) and human 
(right) pancreatic cancer specimens (n = 5  
examined). In addition to the expression in PDA 
neoplastic cells, note expression in endothelial 
(white arrows) and stromal cells (black arrows). 
(B) Expression of Notch target genes Hes1 and 
Hey2 in mouse PanIN and PDA tissue (neoplastic 
cells marked by black arrows). Hey2 expression 
is also noted in intratumoral endothelial cells 
(white arrow; n = 5). (C) In situ hybridization  
in dark and light fields demonstrating Hes1 
expression in pancreatic cancer ductal cells and 
decreased Hes1 expression upon treatment 
with MRK003 (GSI; n = 3). (D) Quantitative 
real-time PCR showing relative mRNA expres-
sion of Notch pathway components in PDA  
tissue from mice treated with vehicle (n = 5) or 
MRK003 (n = 6) for 10 d. (E) Expression of Hes1 
protein in tumors of mice treated with vehicle 
(n = 8) or GSI (n = 6; **, P = 0.003). Representa-
tive images from GSI treated and untreated 
tumors are shown to the right. Error bars repre-
sent SEM. Bars, 100 µm.
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relevant range (Fig. 2 A), albeit lower than MRK003 levels 
measured in the liver and kidney (Fig. 2 B). Interestingly, 
intratumoral MRK003 was modestly decreased by the co-
administration of gemcitabine (Fig. 2 A). Using an LC/MS 
technique that we recently developed (Bapiro et al., 2011), 
we also determined that gemcitabine (dFdC [difluorode-
oxycytidine]) and its inactive (dFdU [difluorodeoxyuridine]) 
and active (dFdCTP [difluorodeoxycytidine triphosphate]) 
metabolites were all slightly decreased in abundance after GSI 
treatment, albeit not significantly (Fig. 2 C). Therefore, MRK003 
is delivered at therapeutic levels, but the concomitant adminis-
tration of MRK003 and gemcitabine modestly antagonize the 
delivery of both agents.
MRK003/gemcitabine combination treatment  
significantly improves survival in the KPC model
Because we found that Notch signaling is prevalent in multi-
ple cellular compartments in mouse pancreatic tumors, we 
examined a role for this pathway in tumor maintenance. A 
survival study was performed in KPC mice, as previously de-
scribed (Olive et al., 2009), comparing vehicle, MRK003, and 
gemcitabine monotherapy cohorts to MRK003/gemcitabine 
combination–treated mice. Although there was no evidence 
of significant single agent activity of MRK003 or gemcitabine 
in PDA, the combination of MRK003 and gemcitabine syn-
ergistically and significantly improved anti-tumor efficacy and 
median survival in the KPC model (median survival vehicle 
9 d vs. 26 d with GSI and gemcitabine; P = 0.002; Fig. 3 A). 
A prominent histological finding in the combination treatment 
group was the significant amount of necrosis in the combination- 
treated tumors (Fig. 3, B and C; P = 0.003). Unlike tumor core 
necrosis, which is commonly observed in xenograft tu-
mors, in KPC tumors combination treatment induced ne-
crosis that occurred in patches scattered throughout the 
tumor. Tumor volumes, measured with high resolution ultra-
sound, were calculated for all mice on study and tumor growth 
rate was estimated for each tumor and each cohort. There was 
no significant difference in tumor volumes at the start of treat-
ment (unpublished data). Tumor shrinkage was not observed, 
although combination treatment with MRK003 and gem-
citabine had a significant effect on halting tumor growth 
(P = 0.002; Fig. 3 D). We found no correlation between final 
tumor size and necrosis or treatment length and necrosis, 
particularly in the treatment cohorts that contained the GSI 
(unpublished data). Tissue obtained at endpoint of the survi-
val studies revealed decreased proliferation and increased cell 
death in MRK003-treated mice but variable effects in the 
MRK003/gemcitabine cohort (unpublished data). To clarify 
the early effects of treatment, KPC tumors were examined after 
10 d of treatment. MRK003 monotherapy significantly inhib-
ited proliferation (P = 0.005; Fig. 3 E), and the combination of 
MRK003 and gemcitabine showed a trend toward decreased 
proliferation (P = 0.07; Fig. 3 E). Additionally, combination-
treated KPC tumors had an elevated content of apoptotic cells 
in comparison to monotherapy (P = 0.02; Fig. 3 F) and control 
treatments (P = 0.008; Fig. 3 F). This increase in apoptosis was 
Hes1 mRNA was detected by in situ hybridization in neoplastic 
cells, and this decreased after treatment with MRK003 (Fig. 1 C). 
Bulk tumor tissue was also analyzed, and quantitative PCR 
of mRNA confirmed that MRK003 modulated a subset of 
Notch pathway genes, particularly those enriched in the stroma, 
including Jagged 1, Notch3, HeyL, and Hey1 (Fig. 1 D). Treat-
ment with MRK003 was well tolerated by mice, despite the 
induction of goblet cell metaplasia (unpublished data) as pre-
viously reported for GSIs (van Es et al., 2005). Although Hes1 
mRNA was not significantly decreased by MRK003 in total 
bulk tumor tissue, likely as a result of the contribution of stromal 
cells in KPC tumors as opposed to xenografts (Plentz et al., 2009), 
the intranuclear protein content of Hes1 was markedly di-
minished in normal intestinal and PDA cells (not depicted 
and Fig. 1 E). Therefore, both neoplastic cells and the tumor 
microenvironment in PanIN and PDA express components of 
the Notch pathway, and perturbations in the pathway can serve 
as pharmacodynamic biomarkers to antagonism by GSI.
Previous work from our laboratory has shown that PDA is 
hypovascular in both humans and the KPC model, and that 
improvement of gemcitabine delivery in the KPC model results 
in the prolongation of survival (Olive et al., 2009). Therefore, 
we determined whether the delivery of MRK003 or gem-
citabine to PDA tumors was compromised. We found that the 
intratumoral level of MRK003 was within a therapeutically 
Figure 2. Intratumoral measurements of MRK003 and gemcitabine 
and tumor volumes. (A) Concentration of MRK003 in PDA tissue after 
monotherapy (n = 6) and GSI/gemcitabine combination treatment (n = 6;  
P = 0.18). (B) Ratio of MRK003 in other organs compared with the amount in 
a tumor in two different mice. (C) Concentration of gemcitabine and its  
metabolites in whole tumor samples (n = 6 on all cohorts). All animals were 
treated for 10 d then sacrificed 1 h after the last dose of gemcitabine and 6 h 
after the last dose of MRK003. Error bars represent SEM.
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of intratumoral vessels within 3 d of treatment (Fig. 4, E and F). 
Notably, KPC intratumoral endothelial cells demonstrated 
decreased protein content of the Notch target genes Hey1 and 
Hey2 after MRK003 treatment (Fig. 4 G). Additionally, 2H11 
mouse endothelial cells demonstrated decreased endothelial 
sprouting in culture after treatment with either gemcitabine 
or MRK003, with the combination providing the greatest 
effect. Examining the 2H11 cell lines also revealed a decrease 
in Jagged1 and Notch3 protein upon treatment with the 
GSI (unpublished data). Collectively, these findings show 
that MRK003 targets Notch signaling to decrease KPC 
endothelial cell survival and vascular function, and that this 
is exacerbated by combination treatment with gemcitabine.
Hypoxia sensitizes KPC tumor cells to growth inhibition by GSI
We reasoned that the reduced intratumoral vascular function 
and density after MRK003/gemcitabine treatment could com-
promise PDA tissue metabolism and survival. Accordingly, 
pimonidazole adduct formation was used to determine whether 
tissue oxygenation was limiting under these conditions (Raleigh 
et al., 1998). We found that MRK003/gemcitabine-treated 
KPC mice had a large increase (four- to fivefold) in tumor 
also significantly different in the GSI-treated cohort com-
pared with vehicle (P = 0.01; Fig. 3 F) and could not be 
attributed to stromal myofibroblasts (not depicted). Therefore, 
the combination of MRK003 and gemcitabine suppresses 
neoplastic cell proliferation and stimulates apoptosis and 
intratumoral necrosis.
MRK003/gemcitabine kills intratumoral endothelial cells and 
synergistically decreases vascular function and density in PDA
The vascular endothelium was also specifically assessed be-
cause the Notch pathway is implicated in vasculogenesis and 
tumor angiogenesis (Phng and Gerhardt, 2009). We found 
that treatment of KPC mice for 3 d with MRK003 alone and 
the combination of MRK003/gemcitabine rapidly induced 
endothelial cell death (P = 0.02 combination treatment com-
pared with vehicle; Fig. 4, A and B). Indeed, the intratumoral 
vasculature was significantly less functional after MRK003/
gemcitabine treatment as measured by perfusion of Lycopersi-
con esculentum lectin (P = 0.008 vs. vehicle; Fig. 4, C and D). 
To a lesser extent, MRK003 monotherapy treatment also re-
vealed this property (Fig. 4, C and D). MRK003/gemcitabine 
combination treatment also significantly decreased the density 
Figure 3. Combination treatment with MRK003 and Gemcitabine prolongs survival in PDA. (A) Survival is extended by the combination treatment of 
GSI and Gemcitabine (median survival vehicle 9 d vs. 26 d with GSI and gemcitabine; P = 0.002; n = 11 vehicle [black], n = 12 gemcitabine [green], n = 10 GSI 
[red], n = 10 GSI and gemcitabine [blue]). (B) Histological representative tumor appearances for each of the cohorts of animals treated in the survival study (bars, 
200 µm). Necrotic areas are outlined. (C) Quantification of necrosis in the survival study (**, P = 0.003; n = 11 vehicle, n = 10 gemcitabine, n = 7 GSI, n = 9 GSI + 
gemcitabine). (D) Quantification of tumor volume growth using twice weekly high resolution ultrasound (**, P = 0.002; n = 10 in all cohorts). (E) Computer-based 
quantification of proliferation (phospho-histone histone H3) in tumors from mice treated for 10 d (**, P = 0.005; GSI n = 5, vehicle n = 10; *, P = 0.07; GSI + gem-
citabine n = 6, vehicle n = 10). (F) Computer-based quantification of apoptosis in tumors from mice treated for 10 d (*, P = 0.008). Combination treatment (n = 6) 
group compared with vehicle (n = 5; **, P = 0.02), gemcitabine (n = 6), and GSI alone (n = 6; *, P = 0.01, GSI compared with vehicle). Error bars represent SEM.
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in response to cytotoxic chemotherapy, thereby sensitizing cells 
to GSI treatment. In contrast, however, we found that PDA 
did not induce NICD-dependent transcription in response 
to gemcitabine treatment in vivo or in culture (unpublished 
data). Additionally, increased susceptibility to gemcitabine 
cytotoxicity was not observed in PDA cell lines upon hypoxic 
incubation (Fig. 5 F). Instead, in accordance with prior studies 
that used normal cells (Gustafsson et al., 2005) and neoplastic 
cells (Sahlgren et al., 2008; Chen et al., 2009), we found that 
hypoxia increased the mRNA expression of several NICD 
target genes, such as Survivin and Notch 3 (Fig. 5 G). Survivin 
and Notch3 have established antiapoptotic roles (Mita et al., 
2008; Indraccolo et al., 2009; Pradeep et al., 2011), and the 
hypoxia-induced elevations in Survivin and Notch3 mRNA 
were selectively repressed by MRK003, providing a mecha-
nistic basis for the sensitivity of PDA cells to GSI while under 
hypoxic conditions.
hypoxia (P = 0.006; Fig. 5, A and B). Interestingly, the amount 
of baseline hypoxia in vehicle-treated KPC tumors was almost 
undetectable (Fig. 5, A and B), despite the hypovascular state 
of this tissue (Olive et al., 2009). To determine whether the 
treatment efficacy of MRK003 and gemcitabine are influenced 
by relative oxygenation levels, tumor cells were placed under 
normoxic and hypoxic conditions and the cell viability was 
measured. Under normoxic conditions, cultured KPC tumor 
cell lines exhibited variable sensitivity to MRK003, with an 
IC50 ranging from 2 to >100 µM (Fig. 5, C and D). Inter-
estingly, hypoxic culturing of the same PDA cells increased the 
cytotoxic effect of MRK003 by up to fivefold (Fig. 5 D), an 
effect which was also observed in HPAF (Fig. 5 E) and Panc-1 
(not depicted) human pancreatic cancer cell lines. This finding 
was reminiscent of previous results indicating that colon 
cancer (Meng et al., 2009) and neuroblastoma cells (Stockhausen 
et al., 2005) in culture activate NICD-dependent transcription 
Figure 4. The combination of MRK003 and gemcitabine synergistically kills intratumoral endothelial cells to decrease vascular function and den-
sity in PDA. (A) Representative immunofluorescence images of DAPI (blue), Meca32 (orange), and Cleaved caspase 3 (CC3; green) content in each of the 3 d–
treated cohorts (n = 3 or more samples evaluated for each cohort). White arrows: CC3-positive endothelial cells; yellow arrow: CC3-positive nonendothelial cell. 
Bars, 10 µm. (B) Percentage of CC3-positive Meca32-expressing endothelial cells in tumor samples treated for 3 d (**, P = 0.008). Vehicle, n = 5; gemcitabine,  
n = 4; GSI, n = 6; GSI and gemcitabine, n = 6. (C) Representative immunofluorescence images of DAPI (blue), Meca32 (green), and Lectin (red) content in each of 
the 3 d–treated cohorts (bars, 50 µm; n = 3 or more samples evaluated for each cohort). (D) Quantification of vascular patency (percentage of lectin and meca32 
positive endothelial cells) in the GSI/gemcitabine combination treatment (n = 5) compared with vehicle (n = 5; **, P = 0.008) or gemcitabine (n = 3; P = 0.004) 
GSI (n = 4; P = 0.06) compared with vehicle. (E) Histological representative Meca32 IHC-stained images for each of the cohorts of animals treated for 10 d.  
Bars, 50 µm. (F) Quantification of MVD in 3 d cohorts reveals a significant decrease in MVD in the GSI/gemcitabine combination treatment (n = 4) cohort 
compared with the gemcitabine (n = 4; P = 0.03), GSI (n = 4; P = 0.03), and vehicle (n = 8; **, P = 0.02) cohorts. All animals were sacrificed 1 h after the last dose  
of gemcitabine and 6 h after the last dose of the GSI. (G) Expression of Hey1 and Hey2 protein in the tumor endothelial cells of mice treated with vehicle or GSI. 
Black arrows: positive endothelial nuclei; red arrows: positive nonendothelial KPC tumor nuclei. Bars, 10 µm. n = 3 for each cohort. Error bars represent SEM.
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in pancreatic cancer without increasing gemcitabine levels, 
and GSIs are an exemplar by targeting both endothelial and 
neoplastic cells in PDA and becoming more potent during 
the ensuing hypoxic necrosis.
This is the first study demonstrating that the dysfunctional 
vasculature in primary PDA tumors represents an attractive 
target for antivascular strategies. Indeed, prior preclinical work 
with genetically engineered mouse models (Singh et al., 2010), 
and multiple clinical trials that used anti-VEGF strategies, failed 
to show benefits in PDA (Van Cutsem et al., 2009; Kindler et al., 
2010). This may reflect a greater dependency of PDA vasculature 
on the Notch pathway rather than VEGF-mediated signaling 
to maintain the intratumoral vasculature. The ability of GSIs to 
prevent pancreatic cancer in mouse models has previously been 
attributed to the antiproliferative affects of these agents (Plentz 
et al., 2009). Although we also find that MRK003 reduces the 
proliferation of neoplastic cells in established PDA tumors, this 
has a negligible impact upon disease progression. Rather, we 
find that MRK003 also destabilizes endothelial cells in established 
PDA tumors, and that in combination with gemcitabine pro-
motes intratumoral vascular regression. We propose that the 
ensuing intratumoral hypoxia sensitizes the neoplastic cells to 
the effects of the GSI by targeting new biochemical dependencies, 
Although we cannot exclude the roles for additional intra-
cellular targets of GSIs (Kopan and Ilagan, 2004; Jorissen and 
De Strooper, 2010), or the effect upon stem-like cells in 
pancreatic tumors (Simeone, 2008; Pannuti et al., 2010), we 
demonstrate that the antivascular effects of GSIs are an im-
portant component in the response of KPC mice to MRK003, 
and that this is greatly exacerbated by the co-administration of 
gemcitabine, leading to vascular regression and intratumoral 
hypoxia. Additionally, although previous studies reported that 
Notch 1 and Notch2 regulated this pathway in similar mouse 
models of pancreatic cancer, we did not observe significant 
alterations in Notch1 or Notch2 mRNA levels in bulk tumor 
tissues in response to GSI (not depicted; Hanlon et al., 2010; 
Mazur et al., 2010). Rather, we observed decreases in Notch3 
protein and mRNA after GSI treatment (Fig. 1, A and D).
We recently reported that stromal depletion with a smooth-
ened inhibitor increased the vascular density in KPC tumors, 
leading to elevated gemcitabine delivery and response (Olive 
et al., 2009). Here, we show that MRK003 and gemcitabine 
effectively synergize to prolong survival in KPC mice, and 
that intratumoral gemcitabine delivery is actually hindered 
during treatment. Therefore, some therapeutics may enhance 
the cytotoxicity of gemcitabine to promote anti-tumor responses 
Figure 5. Treatment-induced hypoxia acutely sensitizes tumor cells to MRK003. (A) Representative immunofluorescence images of pimonidazole hydro-
chloride (Hypoxyprobe-1) staining with areas of hypoxia shown in bright green after 3 d of treatment (bars, 100 µm; n = 4 or more samples evaluated for each 
condition). (B) Levels of hypoxia in tumors treated with the combination treatment (n = 6) compared with vehicle (n = 4; **, P = 0.006) and gemcitabine (n = 4;  
P = 0.02) cohorts. Combination treatment was compared with GSI (n = 6; P = 0.07). GSI treatment was compared with vehicle (P = 0.01). (C) A panel of 10 KPC 
cell lines were tested to determine the GI50 values when treated with GSI under normoxia (units = µM). (D) KPC cell lines were examined for effects of GSI under 
normoxic and hypoxic conditions. The graph shown is representative of 10 cell lines. These experiments were performed in triplicate on three separate occasions 
(*, P < 0.001). (E) Human PDA cells were examined for effects of GSI under normoxic and hypoxic conditions. The graph shown is representative of the HPAF cell 
line. This experiment was performed in triplicate on two separate occasions (*, P < 0.001). (F) KPC cell lines were examined for the cytotoxic activity of gemcitabine 
under normoxic and hypoxic conditions. (G) qRT-PCR of survivin and Notch3 under hypoxia, and after incubation with MRK003. Error bars represent SEM.
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experiments, MRK003 was dosed as a suspension in 0.5% methylcellulose at 
a 10 ml/kg dosing volume, made fresh daily. Before administering each dose 
the compound was thoroughly mixed to distribute suspension evenly. The 
dosing schedule for MRK003 was 100 mg/kg by oral gavage, once daily for 
days 1–3 of each week, which was well tolerated. This schedule has been 
proven to be more tolerable to mouse models, and we therefore continued to 
use this schedule in our studies (Plentz et al., 2009). Gemcitabine was dosed as 
a solution in 0.9% normal saline at a 100 mg/kg solution, via intraperitoneal 
route, twice weekly as previously reported (Olive et al., 2009).
Pharmacokinetic analysis. Plasma, tumor, and normal tissue concentrations 
of MRK003 were evaluated by Merck Pharmaceuticals. Drug was isolated 
from homogenized tissue by acetonitrile extraction, and concentration deter-
mined by liquid chromatography–tandem mass spectrometry. All samples 
were processed by protein precipitation. 300 µl of the appropriate internal 
standard solution was added to each well containing sample, including the 
double blank sample where 300 µl acetonitrile was added. The samples were 
filtered, and then directly diluted with 600 µl of water and analyzed with 
an API 4000 mass spectrometer equipped with an electrospray interface. Gem-
citabine, dFdU, and gemcitabine triphosphate were extracted from tumor 
tissue and quantified essentially as previously described (Bapiro et al., 2011).
Survival studies and Imaging. The structure for the survival study has 
been described previously (Olive et al., 2009) and was refined here by 
restricting enrolment to KPC mice that had tumors with a mean diameter 
between 6 and 9 mm. High resolution ultrasound imaging was performed 
as described previously (Olive et al., 2009).
Statistical analysis and quantification. Statistical analyses were performed 
using Prism version 5.00 for Windows (GraphPad Software). Histological analysis 
was either performed manually or using Ariol software (Leica) for quantification.
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